Results 31 to 40 of about 208,633 (265)
The role of immune checkpoint inhibitors in the development and treatment of infectious processes [PDF]
Клиническая практикаThe incidence and prevalence of oncological diseases, which are the second most frequent cause of death, is steadily increasing among the population of the Russian Federation.
Dilya A. Mustafina +13 more
doaj +1 more source
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
Gynecologic Oncology Reports, 2019 Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with ...
David W. Doo +2 more
doaj +1 more source
Research Progress of Immune Checkpoint Therapy on Colorectal Cancer
Zhongliu Fangzhi Yanjiu, 2021 At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj +1 more source
Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition
JEADV Clinical Practice, 2023 The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer +4 more
doaj +1 more source
Journal of Immunology Research, 2020 Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis +4 more
doaj +1 more source
Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
BMC Pulmonary Medicine, 2021 Background The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM)
Steven G. Gray
doaj +1 more source
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
Vaccines, 2023 Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide.
Jin Zhang +5 more
doaj +1 more source
Translational target for checkpoint inhibitors [PDF]
Nature Reviews Immunology, 2018 Eukaryotic translation initiation complex eIF4F is identified as an upstream regulator of PD-L1 expression and is therefore a promising target for immunotherapy.
openaire +2 more sources
Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]
Journal of NephropharmacologyImmune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar +4 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2023 The exploration of biomarkers predicting response to immune checkpoint inhibitors in microsatellite stability colorectal cancer can enable more patients to benefit from immunotherapy.
WANG Zhiqiang +3 more
doaj +1 more source